OS Benefit from TTFields with Gemcitabine/Nab-paclitaxel for Patients with Unresectable Locally Advanced Pancreatic Adenocarcinoma By Ogkologos - August 4, 2025 779 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PANOVA-3 study Source RELATED ARTICLESMORE FROM AUTHOR Tambotatug Pelitecan Leads to Better Clinical Outcomes than Topotecan Among Patients with Relapsed SCLC After Platinum-based Therapy ESMO Welcomes European Parliament Calls to Strengthen and Protect Europe’s Cancer Workforce No improvement in OS, but more grade 3 or higher AEs with atezolizumab plus SBRT among patients with inoperable early-stage NSCLC MOST POPULAR Ethnic Diversity and Disparities in Access to Genetic Testing Impact Prostate... November 28, 2022 Exploring Coping Resources to Help with Physical, Practical, and Emotional Challenges... January 8, 2024 News digest – light-activated nanoparticles, Government’s obesity plans, tumour ‘glue’ and... July 11, 2020 Fruquintinib Prolongs Survival Compared with Placebo in Heavily Pretreated Patients with... June 27, 2023 Load more HOT NEWS Cancer Research UK’s charity Christmas cards now available 10 Ways to Brave Cancer Treatment: Tips from a Survivor ΚΑΡΚΙΝΟΣ ΕΝΔΟΜΗΤΡΙΟΥ Georgia Middle Schooler Donates All the Proceeds of Her Grand Champion...
